Trilliant Health collaborates with Duke Health to support decision making
This strategic alliance will utilise Trilliant's analytics platform to support network design, growth planning, and access of the patients, in line with the needs and behaviours of the communities Duke Health serves.
Duke Health chief strategy officer Morgan Jones said: 'Our ability to plan effectively for strategic growth is dependent upon understanding the communities we serve.
'Applying predictive analytics allows us to understand real patterns of care, behaviour and community need.'
Trilliant Health's tools will provide Duke Health with predictive analytics for facility and service planning, customised to the requirements of local communities.
The solutions will also offer psychographic segmentation for patient engagement, and network integrity analysis to enhance referral retention.
Additionally, these tools are designed to help pinpoint underserved areas, enhancing delivery of service, and inform consumer outreach and marketing efforts.
Trilliant Health president and CEO Hal Andrews said: 'By integrating data science and behavioral insight into strategic planning, health systems can better position themselves to meet the evolving expectations of healthcare consumers.'
The partnership is set to enhance patient satisfaction and loyalty, optimise utilisation of capital, and increase access to healthcare.
It comes at a time when the healthcare industry is increasingly moving towards outpatient and unconventional settings, providing a scalable, evidence-based foundation for growth.
In May this year, Duke Health expanded its specialty pharmacy services through a partnership with Shields Health Solutions. The collaboration is aimed at advancing clinical care and improving health outcomes in North Carolina through the expansion.
"Trilliant Health collaborates with Duke Health to support decision making" was originally created and published by Hospital Management, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Cigna (CI) Pullback a Buying Opportunity, Says TD Cowen with a Buy Rating
The Cigna Group (NYSE:CI) is one of the best defensive stocks to invest in according to analysts. Cigna shares cracked over 10% on July 31 after the company reported its Q2 2025 quarterly results. Following the results, TD Cowen analyst Charles Rhyee reiterated a Buy rating on Cigna, maintaining a $387 price target. He believes the recent pullback in the shares was overdone and sees current levels as an attractive entry point. A health care professional consulting with patients in a state-of-the-art facility. While concerns around performance in the Health Insurance Exchange (HIX) segment weighed on sentiment, Rhyee expects the impact to be limited. He points to strength in other parts of the business, particularly Specialty and Care Services, as well as solid momentum in the company's Pharmacy Benefit Management (PBM) operations, which should help offset pressures. Rhyee also noted that management's Q3 guidance appears cautious, especially considering stepped-up investment in improving patient experience. Still, he remains confident in the company's earnings outlook, with robust EPS growth projections for 2025 and 2026 supporting his valuation. The Cigna Group (NYSE:CI) is a health services company that provides medical, pharmacy, behavioural health, dental, and supplemental insurance products. While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and 10 Most Oversold Semiconductor Stocks So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Wells Fargo Sticks with Overweight on UnitedHealth (UNH), Trims Target to $267
UnitedHealth Group Inc. (NYSE:UNH) is one of the best defensive stocks to invest in according to analysts. At the time of writing this article, UnitedHealth ranks among the 10 biggest year-to-date decliners, which have lost over 50% among U.S.-listed stocks with a market capitalization exceeding $2 billion. The company, which was marred by government investigations, operational failures, and leadership changes, reported mixed Q2 2025 earnings results at the end of July. Those results have been unable to shore up the share price, as the long-term growth outlook is still murky. A close-up of a healthcare professional studying a computer screen with data while consulting with a patient. The company guided for 2025 adjusted EPS to be over $16, which was significantly below Bloomberg's consensus expectations of $20.4. Seeing the brighter side, Jeff Jonas, portfolio manager at Gabelli Funds, called the guidance highly conservative and believes that it will be easier for the company to beat such low expectations. However, the steep correction and valuation discount have attracted analysts' interest, with around two-thirds of them having a Buy or equivalent rating. One of the analysts who maintains an optimistic view is Wells Fargo's Stephen Baxter. On August 4, Baxter maintained an Overweight rating on UnitedHealth but lowered his price target to $267 from $306. The revision followed a recently held management meeting where he assessed the company's updated outlook. According to the analyst, UnitedHealth's management remains confident in the company's ability to meet its reset 2025 guidance. In his view, management is taking a cautious but disciplined approach in factoring in cost trends and margin recovery. Baxter views this conservatism positively, suggesting it reduces the risk of further downside revisions. UnitedHealth Group Inc. (NYSE:UNH) is a healthcare company that provides health insurance and healthcare solutions in the U.S. and globally under the UnitedHealthcare and Optum brands. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and 10 Most Oversold Semiconductor Stocks So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
36 minutes ago
- Yahoo
Gold Futures Fall From Record High as White House Expected to Issue Clarification on Bullion Tariffs
US gold futures reached an all-time high Friday amid speculation that the yellow metal's imports may Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
